NetworkNewsBreaks – Mydecine Innovations Group (
Post# of 160
(Total Views: 212)
Posted On: 12/01/2021 3:53:24 PM
NetworkNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Reimagining Mental Health, Addiction Treatment
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, recently filed a patent application covering bioavailability-enhancing, nanoemulsion-empowered formulations. The move followed on the heels of a previous announcement that the company had filed a final patent application for MYCO-003, one of its lead drug candidates. Nanoemulsion is an advanced drug delivery system that offers enhanced stability, fast digestibility, controlled release and protection against degradation. “Specifically, Mydecine is targeting the enhanced bioavailability and controlled capabilities of the nanoemulsion technology. The system’s controlled-release capability, for example, will be instrumental in the company’s active drug development by aiding in micro-dosing and customizing dosages,” reads a recent article. “Through its latest technology patent filing, coupled with the September final patent application, the company is steadily strengthening its intellectual property (‘IP’) portfolio as it seeks to reimagine mental health and addiction treatment with safer, more effective solutions.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, recently filed a patent application covering bioavailability-enhancing, nanoemulsion-empowered formulations. The move followed on the heels of a previous announcement that the company had filed a final patent application for MYCO-003, one of its lead drug candidates. Nanoemulsion is an advanced drug delivery system that offers enhanced stability, fast digestibility, controlled release and protection against degradation. “Specifically, Mydecine is targeting the enhanced bioavailability and controlled capabilities of the nanoemulsion technology. The system’s controlled-release capability, for example, will be instrumental in the company’s active drug development by aiding in micro-dosing and customizing dosages,” reads a recent article. “Through its latest technology patent filing, coupled with the September final patent application, the company is steadily strengthening its intellectual property (‘IP’) portfolio as it seeks to reimagine mental health and addiction treatment with safer, more effective solutions.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)